Veristat has completed the validation and configuration of Master Control’s eTMF system, which is now implemented and available for Veristat managed clinical trials.
Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.
SOUTHBOROUGH, MA – June 19, 2017 – Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA).
Employees at Veristat handle complex work that is both rewarding and meaningful. Our team members are dedicated partners to internal colleagues and external clients alike.
Our values include:
If this sounds like an environment you would thrive in, then click below to learn more about us.
Since the day Veristat was formed, our approach has focused on partnership. We aren’t here to complicate your studies, we are here to be a true extension of your team, to build enduring partnerships, to be a trust-worthy teacher and respected team member.
We are here to be TRUE Partners to You.
Our teams support amazing, cutting-edge, life-enhancing and life-saving therapies that range from novel vaccines for global pandemics to new approaches for treating fungal infections to the latest immunotherapies to eradicate cancer. We have the right expertise and therapeutic understanding and creative know-how to help you design, build, and run your clinical development program in any therapeutic area.
Our current ongoing projects focus for therapies to treat Cancers, Rare Diseases, Neurological Disorders, Cardiovascular Disease, Infectious Diseases and more.
